ETNB Key Statistics, Chart & Performance
The current stock price of ETNB is 14.84 USD. In the past month the price increased by 1.02%. In the past year, price increased by 62.36%.
ETNB Latest News, Press Relases and Analysis
ETNB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.4 | 407.30B | ||
| AMGN | AMGEN INC | 15.28 | 179.91B | ||
| GILD | GILEAD SCIENCES INC | 15.38 | 156.33B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 109.55B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.95 | 80.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 842.14 | 56.30B | ||
| INSM | INSMED INC | N/A | 43.34B | ||
| NTRA | NATERA INC | N/A | 32.58B | ||
| BIIB | BIOGEN INC | 10.57 | 25.93B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.12 | 21.63B | ||
| INCY | INCYTE CORP | 16.47 | 20.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About ETNB
Company Profile
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company is headquartered in San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2019-11-11. The firm is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.
Company Info
89BIO INC
655 Montgomery Street, Suite 1500
San Francisco CALIFORNIA 94104 US
CEO: Rohan Palekar
Employees: 93
Phone: 14154329270
89BIO INC / ETNB FAQ
What does 89BIO INC do?
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company is headquartered in San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2019-11-11. The firm is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.
What is the current price of ETNB stock?
The current stock price of ETNB is 14.84 USD.
What is the dividend status of 89BIO INC?
ETNB does not pay a dividend.
How is the ChartMill rating for 89BIO INC?
ETNB has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is 89BIO INC worth?
89BIO INC (ETNB) has a market capitalization of 2.20B USD. This makes ETNB a Mid Cap stock.
When does 89BIO INC (ETNB) report earnings?
89BIO INC (ETNB) will report earnings on 2026-02-25, after the market close.
Can you provide the ownership details for ETNB stock?
You can find the ownership structure of 89BIO INC (ETNB) on the Ownership tab.
ETNB Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ETNB. When comparing the yearly performance of all stocks, ETNB is one of the better performing stocks in the market, outperforming 94.47% of all stocks.
ETNB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ETNB. While ETNB seems to be doing ok healthwise, there are quite some concerns on its profitability.
ETNB Financial Highlights
Over the last trailing twelve months ETNB reported a non-GAAP Earnings per Share(EPS) of -3.61. The EPS decreased by -83.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.6% | ||
| ROE | -86.29% | ||
| Debt/Equity | 0.07 |
ETNB Forecast & Estimates
11 analysts have analysed ETNB and the average price target is 29.52 USD. This implies a price increase of 98.9% is expected in the next year compared to the current price of 14.84.